83 
Amgen partners with Arrakis to develop drugs aimed at RNA
Bio Pharma Dive
JANUARY 11, 2022
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more
RNA Related Topics 
Moderna founder unveils new drug company focused on a different kind of RNA
Bio Pharma Dive
NOVEMBER 9, 2021
The biotech is researching how to make medicines from transfer RNA molecules Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Moderna founder launches new biotech, looking to cure diseases through 'endless RNA'
Bio Pharma Dive
MAY 10, 2021
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines
COVID-19 : Measuring viral RNA to predict which patients will die
Scienmag
NOVEMBER 26, 2021
Credit: CHUM The amount of a SARS-CoV-2 genetic material—viral RNA—in the blood is a reliable indicator in detecting which patients will die of the disease, a team led by Université de Montréal medical professor Dr.?Daniel Medicine & Health COVID19 die Measuring Patients predict RNA vira
As Arrowhead falters, lungs remain a tough target for RNA drugs
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs
BioTuring enters collaboration to enable detailed single-cell RNA research
Pharma Phorum
JANUARY 19, 2022
The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. News R&D pharma rna rna therapeutics Single Cell Analysis
Venture capital pours more money into RNA medicines with the launch of Replicate
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen
Peanut studies reveal surprising truths about RNA and open the door to better understanding epigenetic mechanisms in plants
Scienmag
JANUARY 13, 2022
Medicine & Health door epigenetic mechanisms open Peanut plants reveal RNA Studies surprising truths UnderstandingPlants encounter microbes all the time, in the air, water, and soil. Some cause disease, others are neutral, but a few microbes promote plant health and growth.
Moderna founder's next big play in RNA raises $440 million
Bio Pharma Dive
AUGUST 30, 2021
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus
Eli Lilly Pursues RNA Editing in New Partnership with ProQR
XTalks
SEPTEMBER 13, 2021
billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization.
Roche adds to RNA drug deal streak with Ribometrix partnership
Bio Pharma Dive
JANUARY 6, 2021
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules
How RNA-Based Pesticides Can Improve Pest Control
XTalks
NOVEMBER 9, 2021
Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. What are RNA-Based Pesticides? Advantages of RNA-Based Pesticides.
Lilly joins RNA editing race with ProQR deal
Bio Pharma Dive
SEPTEMBER 9, 2021
An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research
|
GSK dives into NASH, RNA interference with Arrowhead deal
Bio Pharma Dive
NOVEMBER 23, 2021
GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers
Researchers identify key RNA “gatekeeper” in gene expression, pointing to possible new drug targets
Scienmag
DECEMBER 1, 2021
Latest News Drug expression gatekeeper gene identify key pointing researchers RNA targetsBOSTON – An important player in the healthy development of female embryos turns out also to play a key role in regulating the behavior of chromosome loops and gene expression in both sexes, according to a new study by researchers at Massachusetts General Hospital (MGH). These findings, reported in the journal Cell, could help create […].
Roivant joins RNA splicing push with Eisai deal
Pharma Phorum
JANUARY 6, 2022
Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.
Scipio bioscience Launches Commercialization in Europe of Asteria©, its RNA Sequencing Kit
BioTech 365
JANUARY 26, 2022
Scipio bioscience Launches Commercialization in Europe of Asteria©, its RNA Sequencing Kit Scipio bioscience Launches Commercialization in Europe of Asteria©, its RNA Sequencing Kit A scientific revolution to perform the key steps of RNA sequencing on individual cells more efficiently … Continue reading → Business Wire
RNA Therapeutics Experience Renaissance Amidst Global Pandemic
BioSpace
AUGUST 4, 2021
RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins
Regulating the ribosomal RNA production line
Scienmag
JANUARY 22, 2021
coli enzyme synthesizing ribosomal RNA that shift it between turbo- and slow-modes depending on the bacteria’s growth rate Credit: Murakami Laboratory, Penn State The enzyme that makes RNA from a DNA template is altered to slow the production of ribosomal RNA (rRNA), the […].
Scientists develop an RNA-based breath test to detect COVID-19
Scienmag
DECEMBER 13, 2021
Philadelphia, December 13, 2021 – In a new study in The Journal of Molecular Diagnostics, published by Elsevier, investigators report on the design and testing of a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2.
Lucerna is Illuminating the Mysteries of RNA to Solve Disease
BioSpace
SEPTEMBER 8, 2021
The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases
Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal
Pharma Phorum
MAY 12, 2021
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs
Biogen taps Envisagenics’ AI to speed up RNA splicing R&D
Pharma Phorum
MAY 14, 2021
Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form.
2nd RNA Editing Summit 2020
Pharma Phorum
OCTOBER 5, 2020
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on.
Prions may channel RNA’s messages
Scienmag
NOVEMBER 15, 2021
HOUSTON – (Nov. 15, 2021) – Prions get mostly bad press, but they may be the keys to controlling protein synthesis in cells. Credit: Xinyu Gu/Rice University HOUSTON – (Nov. 15, 2021) – Prions get mostly bad press, but they may be the keys to controlling protein synthesis in cells.
RNA holds the reins in bacteria: U-M researchers observe RNA controlling protein synthesis
Scienmag
APRIL 14, 2021
Credit: Surajit Chatterjee To better understand how RNA in bacteria gives rise to protein–and along the way, target these processes in the design of new antibiotics–researchers are turning their attention to the unique way this process happens in bacteria.
3rd RNA-Targeted Drug Discovery Summit
Pharma Phorum
SEPTEMBER 1, 2020
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit.
‘Endless RNA’ startup Laronde raises $440m to fuel pipeline
Pharma Phorum
AUGUST 31, 2021
Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. News R&D Flagship Pioneering Laronde Moderna rna
Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine
BioTech 365
JANUARY 17, 2022
Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine HDT Bio’s RNA-based vaccine offers simpler … Continue reading → Business Wire
Oncotarget: Urine RNA reveal tumor markers for human bladder cancer
Scienmag
JULY 8, 2021
Oncotarget published “Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection” which reported that in case of bladder cancer, […].
Global RNA Delivery Technology Vendors Benchmark Report 2021 – ResearchAndMarkets.com
BioTech 365
DECEMBER 6, 2021
Global RNA Delivery Technology Vendors Benchmark Report 2021 – ResearchAndMarkets.com Global RNA Delivery Technology Vendors Benchmark Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global RNA Delivery Technologies, 2021: Frost Radar Report” report has been added to ResearchAndMarkets.com’s offering.
Biogen, Ionis tout data from early study of RNA-based Alzheimer's drug
Bio Pharma Dive
JULY 27, 2021
The companies said that patients treated with their experimental drug BIIB080 had reductions in a protein called tau, which research indicates is tied to Alzheimer's but isn't yet proven to impact the course of the disease
#news #biotech Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology
BioTech 365
SEPTEMBER 29, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology.After a gene is transcribed into RNA, modifications can occur to the subunits or “bases” that … Continue reading → #news
Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics
BioTech 365
JANUARY 5, 2022
Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics FOXBOROUGH, Mass.–(BUSINESS Suono Bio, Inc.
Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com
BioTech 365
OCTOBER 21, 2021
Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com Global RNA Analysis Market Research Report 2021 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Global RNA Analysis Market 2021-2026” report has been added to ResearchAndMarkets.com’s offering. This study offers a global view of RNA … Continue reading → Business Wire
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
BioTech 365
JANUARY 19, 2022
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology Financing co-led by venBio … Continue reading → Business Wire
RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com
BioTech 365
JANUARY 14, 2022
RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com RNA Analysis / Transcriptomics Market Report 2021 – Global Trajectory & Analytics to 2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis / Transcriptomics – Global … Continue reading → Business Wire
Parse Biosciences Announces Partnership With Research Instruments Group to Offer RNA-Seq Kits in Singapore and Southeast Asia Region
BioTech 365
JANUARY 18, 2022
Parse Biosciences Announces Partnership With Research Instruments Group to Offer RNA-Seq Kits in Singapore and Southeast Asia Region Parse Biosciences Announces Partnership With Research Instruments Group to Offer RNA-Seq Kits in Singapore and Southeast Asia Region Previously available in North … Continue reading → Business Wire
NSF backs bioinformatics approach to understanding plant RNA modifications
Scienmag
AUGUST 4, 2020
Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins.
RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 13, 2021
RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Scientists behind RNA-repairing strategy recognized with American Chemical Society’s Nobel Signature award
Scienmag
SEPTEMBER 29, 2021
Let's personalize your content